Outcomes in patients with sarcoidosis and COVID-19

Main Article Content

Owais Nadeem
Amreeta Sharma
Diana Alaouie
Patrick Bradley
Dan Ouellette
Raef Fadel
Geehan Suleyman


Sarcoidosis, COVID-19, Immunosuppression therapy


Background and aim: The effect of COVID-19 in patients with sarcoidosis has not been fully explored. The aim was to conduct a retrospective cohort study investigating outcomes in patients with sarcoidosis who were hospitalized with COVID-19.

Methods: We included patients who had diagnoses of sarcoidosis and COVID-19 between January 1, 2020, and February 28, 2021. Primary outcomes included development of critical COVID-19; need for supplemental oxygen, noninvasive ventilation, and invasive ventilation; and death. Association of comorbidities and immunosuppression therapy with outcomes were analyzed. Multiple logistic regression analysis was used to assess risk factors associated with critical COVID-19.

Results: Of 1198 patients with COVID-19, 169 had sarcoidosis (14.1%) and 1029 (85.9%) did not (control group). Of the 169 patients with sarcoidosis and COVID-19, 84 (49.7%) were hospitalized (study group: mean age 62.4 years; 61.9% women; and 56.0% Black). The study group required supplemental oxygen (81% vs 62%; p = 0.001) and noninvasive ventilation (33.3% vs 6.4%; p < 0.001) more often and had lower mortality (15.5% vs. 30.4%; p = 0.004) than the control group. In patients hospitalized with COVID-19, sarcoidosis was not associated with critical COVID-19 (odds ratio, 0.77; 95% CI, 0.46-1.29; p = 0.317), but having sarcoidosis while taking immunosuppression therapy was associated with decreased risk of critical COVID-19 (odds ratio, 0.45; 95% CI, 0.31-0.65; p < 0.001).

Conclusions: Patients with sarcoidosis may not be at increased risk of critical illness or death from COVID-19, and immunosuppression therapy in these patients may reduce the risk of critical COVID-19.


Download data is not yet available.
Abstract 308 | PDF Downloads 235


1. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-9. doi: 10.1164/ajrccm.164.10.2104046.
2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62. doi: 10.1016/S0140-6736(20)30566-3.
3. Sweiss NJ, Korsten P, Syed HJ, et al. When the game changes: guidance to adjust sarcoidosis management during the coronavirus disease 2019 pandemic. Chest 2020; 158: 892-5. doi: 10.1016/j.chest.2020.04.033.
4. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79: 667-8. doi: 10.1136/annrheumdis-2020-217424.
5. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020; 201: e26-51. doi: 10.1164/rccm.202002-0251ST.
6. Morgenthau AS, Levin MA, Freeman R, Reich DL, Klang E. Moderate or severe impairment in pulmonary function is associated with mortality in sarcoidosis patients infected with SARS-CoV-2. Lung 2020; 198: 771-5. doi: 10.1007/s00408-020-00392-9.
7. Jeny F, Lhote R, Lorillon G, et al. Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis.’ Ann Rheum Dis 2020. doi: 10.1136/annrheumdis-2020-218957.
8. Hadi YB, Lakhani DA, Naqvi SFZ, Singh S, Kupec JT. Outcomes of SARS-CoV-2 infection in patients with pulmonary sarcoidosis: a multicenter retrospective research network study. Respir Med 2021; 187: 106538. doi: 10.1016/j.rmed.2021.106538.
9. Baughman RP, Lower EE. COVID-19 infections in sarcoidosis: a prospective single center study of 886 sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2021; 38: e2021029. doi: 10.36141/svdld.v38i2.11646.
10. Hertanto DM, Wiratama BS, Sutanto H, Wungu CDK. Immunomodulation as a potent COVID-19 pharmacotherapy: past, present and future. J Inflamm Res 2021; 14: 3419-28. doi: 10.2147/JIR.S322831.
11. Meyerowitz EA, Sen P, Schoenfeld SR, et al. Immunomodulation as treatment for severe coronavirus disease 2019: a systematic review of current modalities and future directions. Clin Infect Dis 2021; 72: e1130-43. doi: 10.1093/cid/ciaa1759.
12. Esposito AJ, Menon AA, Ghosh AJ, et al. Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study. Am J Respir Crit Care Med 2020; 202: 1710-3. doi: 10.1164/rccm.202006-2441LE.
13. Drake TM, Docherty AB, Harrison EM, et al. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. Am J Respir Crit Care Med 2020; 202: 1656-65. doi: 10.1164/rccm.202007-2794OC.
14. Gallay L, Uzunhan Y, Borie R, et al. Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease. Am J Respir Crit Care Med 2021; 203: 245-9. doi: 10.1164/rccm.202007-2638LE.
15. Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 2020; 79: 1544-9. doi: 10.1136/annrheumdis-2020-218296.
16. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020; 79: 859-66. doi: 10.1136/annrheumdis-2020-217871.
17. Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021; 80: 930-42. doi: 10.1136/annrheumdis-2020-219498.
18. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384: 693-704. doi: 10.1056/NEJMoa2021436.